Filing summary
Entity discrepancy: The request identifies Adicet Bio, Inc., but the supplied Form 10-Q is for resTORbio, Inc. (Nasdaq: TORC). The summary below reflects the supplied filing, not an Adicet Bio filing.
Business context and reporting period
Clinical-stage biopharmaceutical company developing RTB101, a TORC1 inhibitor for aging-related conditions. This unaudited quarterly report covers the three months ended March 31, 2019, with comparisons to the three months ended March 31, 2018. The company had generated no product revenue.
Financial performance and position
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $8.9 million | $8.1 million; up 9% |
| General and administrative expense | $2.8 million | $2.1 million; up 36% |
| Total operating expenses | $11.7 million | $10.2 million |
| Other income, net | $0.6 million | $0.3 million |
| Net loss | $11.1 million | $9.9 million |
| Basic and diluted loss per share | $0.38 | $0.46 |
| Net cash used in operating activities | $12.0 million | $7.3 million |
Cash, cash equivalents and marketable securities totaled $143.1 million at March 31, 2019, including $135.9 million of marketable securities; total current liabilities were $4.6 million. The balance sheet reports no debt. The company said it had no credit facility or committed sources of capital. Operating cash use increased year over year; the reported $34.6 million investing cash outflow primarily reflected purchases of marketable securities, partly offset by maturities. A March public offering generated approximately $46.6 million net proceeds. Cash and cash equivalents ended the quarter at $7.2 million. Profitability and operating margins are not meaningful given the absence of revenue and continuing losses.
Material changes and notable items
- Operating expenses rose $1.5 million year over year, reflecting higher R&D and G&A costs; management attributed R&D spending mainly to clinical trials, preclinical work, materials and personnel.
- Common shares outstanding increased from 28.1 million at December 31, 2018 to 35.3 million at March 31, 2019, largely from the March offering of 7.2 million shares.
- After quarter-end, the company sold another 487,934 shares under the offering option, receiving approximately $3.1 million net.
- In May 2019, Phase 3 initiation triggered a $2.5 million Novartis milestone payment. The filing also describes a May NIH grant award of up to $1.5 million over five years.
Outlook, risks and contingencies
The company expected to report top-line results from both PROTECTOR Phase 3 trials in mid-2020; the second trial was planned to begin in the Northern Hemisphere in Q4 2019. It also expected results from a Phase 1b/2a Parkinson’s disease trial in 2020. Management said existing cash, cash equivalents and marketable securities were expected to fund operations through 2020, including the Phase 3 program and an assumed successful-outcome NDA filing; the liquidity note separately said resources would cover at least the next 12 months. Management cautioned that these estimates depend on assumptions and that additional financing may be needed.
Key risks include clinical-trial execution and outcomes, regulatory approval, future financing availability, development and manufacturing costs, and dependence on third-party research and manufacturing providers. Phase 2 findings cited by management are not assurance of Phase 3 success. The filing reports no material legal proceedings, no material changes to previously disclosed risk factors, and no off-balance-sheet arrangements. A post-quarter lease amendment provides for a seven-year office lease with initial annual base rent of $0.6 million, increasing 2% annually.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is resTORbio, not Adicet Bio.
- Check Phase 3 trial initiation, enrollment, endpoint and data timing against subsequent company disclosures.
- Assess cash runway using actual operating burn, trial costs, the April offering proceeds and the stated financing assumptions.
- Verify the timing and accounting treatment of the $2.5 million Novartis milestone and the NIH grant.
- Review dilution from the public offerings and outstanding equity awards when assessing per-share exposure.